Analysis

Revamped Cancer Drugs Fund urged to monitor outcomes

A revamped Cancer Drugs Fund (CDF) is due to be launched in April, but the public accounts committee (PAC) has warned that NHS England must set out the fund’s objectives and be prepared to take tough decisions to ensure that it does not overspend in trying to meet them.

A revamped Cancer Drugs Fund (CDF) is due to be launched in April, but the public accounts committee (PAC) has warned that NHS England must set out the fund’s objectives and be prepared to take tough decisions to ensure that it does not overspend in trying to meet them.

The CDF was set up by the government in 2010 to improve patient access to cancer drugs not routinely available on the NHS. Initially run by the ten strategic health authorities, since April 2013 it has been managed by NHS England. Scotland has its own system, while Wales and Northern Ireland follow National Institute for Health and Care Excellence (NICE) guidance.

The fund has been mired in controversy with spiralling costs and an expected overspend of between £70 million and £90 million for 2015-16. The budget for the CDF was set initially at £200 million, but has been increased

...

Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?

Jobs